TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04817904
Drug: Rosuvastatin 10mg
Normalized name: ROSUVASTATIN 10MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The statin-treated arm will receive Rosuvastatin tablets 10 mg/day starting from the point of cisplatin initiation through the entire duration of therapy
Study: NCT02236520
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02236520
Drug: Chlorthalidone
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01083784
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group
Study: NCT02236520
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01609907
Drug: Rosuvastatin+Valsartan (Sequence 1)
Normalized name: rosuvastatin and valsartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1(A) Period 2(B) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
Study: NCT01609907
Drug: Rosuvastatin+Valsartan (Sequence 2)
Normalized name: rosuvastatin and valsartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1(C) Period 2(A) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
Study: NCT01609907
Drug: Rosuvastatin+Valsartan (Sequence 3)
Normalized name: rosuvastatin and valsartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1(B) Period 2(C) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
Study: NCT01609907
Drug: Rosuvastatin+Valsartan (Sequence 4)
Normalized name: valsartan 4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1(C) Period 2(B) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
Study: NCT01609907
Drug: Rosuvastatin+Valsartan (Sequence 5)
Normalized name: rosuvastatin 5 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Period 1(B) Period 2(A) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
Study: NCT01609907
Drug: Rosuvastatin+Valsartan (Sequence 6)
Normalized name: valsartan 6 MG
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Period 1(A) Period 2(C) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
Study: NCT01910259
Drug: Amiloride
Normalized name: Amiloride
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison with placebo
Study: NCT01910259
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison with placebo
Study: NCT01910259
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT03936556
Drug: Marketed toothpaste
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed stannous fluoride (0.454%) toothpaste
Study: NCT03936556
Drug: Marketed Cavity Protection Toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed sodium monofluorophosphate (0.76 %) toothpaste
Study: NCT03494179
Drug: ICP-022
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug product is a white, round, uncoated tablet.
Study: NCT02238275
Drug: Micardis® plus
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02152163
Drug: IV Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02152163
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01065610
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02705469
Drug: ZEN003694
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00766532
Drug: Aromatase Inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any aromatase inhibitor started as initial adjuvant therapy
Study: NCT00381342
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection, volume equivalent to appropriate dose of exenatide, twice a day
Study: NCT01908764
Drug: AL-60371 otic suspension
Normalized name: acetic acid
DrugBank: Acetic acid (DB03166)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03237377
Drug: Standard of care adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients may or may not proceed to adjuvant chemotherapy post trial drug and radiation intervention and surgery
Study: NCT01621633
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04575558
Drug: Hydroxychloroquine and Azithromycin
Normalized name: cefixime and azithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine 400mg PO BID 2 times a day + Azithromycin 500mg PO QD
Study: NCT04553133
Drug: PF-07104091 monotherapy dose escalation
Normalized name: Influenza, high-dose, quadrivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-07104091 will be administered orally
Study: NCT04553133
Drug: PF-07104091 monotherapy dose expansion (ovarian)
Normalized name: Influenza, high-dose, quadrivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-07104091 will be administered orally
Study: NCT04553133
Drug: PF-07104091 monotherapy dose expansion (SCLC)
Normalized name: Influenza, high-dose, quadrivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-07104091 will be administered orally
Study: NCT01836432
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine consisting of 825 mg/m\^2 PO BID M-F concurrently with external beam radiation
Study: NCT01686620
Drug: BIOD-123
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03553342
Drug: Corticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive corticosteroids therapy: 1mg/kg of prednisolone daily for seven days.
Study: NCT02698267
Drug: BIIB074
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT00209625
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00209625
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00794456
Drug: Passiflora ; Crataegus and Salix
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet PO twice a day
Study: NCT03945526
Drug: Astaxanthine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03945526
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01136174
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo BID for cohort 1,2,3
Study: NCT01136174
Drug: BIBF 1120
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively
Study: NCT03727620
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients were administered 200 mg of Longamycine the first day and 100 mg per day for 14 days
Study: NCT01549080
Drug: Yisuishengxue Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yisui Shengxue Granules，produced by pharmaceutical factory of Guang'anmen Hospital, China Academy of Chinese Medical Sciences, is made from the herbs of Shan Zhu Yu (Fructus Corni), He Shou Wu (Radix Polygoni Multiflori), Shu Di Huang (Radix Rehmanniae Preparata), Huang Qi (Radix Astragali) and etc.Yisui Shengxue Granules：12g/bag， Registration Number：20110602； Yisui Shengxue Granules replacer (placebo)：12g/bag，Registration Number：20110519；Treatment group：Yisui Shengxue Granules，1 bag, tid, po； Control group: Yisui Shengxue Granules replacer (placebo), 1 bag, tid, po; Intervention for 12 weeks. Follow-up 3 months later after stopping the drug intervention.
Study: NCT00354770
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily
Study: NCT03158675
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid will be applyed twice weekly on both sides for 4 months.
Study: NCT00876187
Drug: Placebo for naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo for naproxen twice a day for 16 weeks
Study: NCT00876187
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral naproxen 500 mg twice a day for 16 weeks
Study: NCT03882814
Drug: Placebo - Concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular saline was administered to the control group as placebo. Salin intramuscular (IM) injection was performed when cervical dilatation was at or greater than 4 cm and the cardiotocogram uterine contraction recordings of 200 Montevideo units was reached. salon was given following amniotomy.
Study: NCT00848055
Drug: AbGn168 intravenous infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose intravenous infusion
Study: NCT00848055
Drug: AbGn168 subcutaneous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose subcutaneous injection
Study: NCT04536688
Drug: RGLS4326
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for subcutaneous injection
Study: NCT00801879
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment 0.25g in each nostril twice daily for 5 days (repeated monthly for up to 8 months)
Study: NCT01072214
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01381432
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: At the start of treatment, 2 to 3 mg per kg of body weight each day. For the rest of treatment, 1 to 2 mg per kg of body weight each day.
Study: NCT00001498
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00001498
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00001498
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00001498
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02173574
Drug: EDP239
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00331045
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01765920
Drug: Ergoferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml 3 times a day
Study: NCT01765920
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml 3 times a day
Study: NCT03588039
Drug: Oraxol
Normalized name: doxycycline hyclate Oral Capsule [Oraxyl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral paclitaxel will be supplied in capsules and oral HM30181AK-US will be supplied in tablets
Study: NCT01902264
Drug: EE20/DRSP/L-5-MTHF (Beyaz, BAY98-7071)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet DRSP 3 mg/EE 0.02 mg/ Levomefolate calcium 0.451 mg daily for 24 days, followed by one hormone-free tablet L-5-MTHF 0.451 mg daily for 4 days over 24 weeks
Study: NCT00712699
Drug: Sequence 1: XR-MAS then placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: XR-MAS given in non-identifying 5 mg capsules with instructions to start 1 capsule (5 mg/d) for one week, then increase to 2 capsules (10 mg/d) for week two, and 3 caps (15 mg/d) for week 3 following flexible, forced titration based on response and tolerance.
Study: NCT00712699
Drug: Sequence 2 Placebo then XR-MAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBO given in non-identifying 5 mg capsules with instructions to start 1 capsule (5 mg/d) for one week, then increase to 2 capsules (10 mg/d) for week two, and 3 caps (15 mg/d) for week 3 following flexible, forced titration based on response and tolerance.
Study: NCT00732563
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV and Orally
Study: NCT00506662
Drug: insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treat-to-target, s.c. (under the skin) injection, once daily
Study: NCT01104025
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal Methotrexate and hydrocortisone will be administered to CNS+ patients (CNS+ patients are those patients which have any of the following: elevated CSF (cerebral spinal fluid) protein or white count, seizures, focal or global neurologic deficit, MRI abnormalities consistent with CNS involvement by HLH.) in the following doses: age\< 1 yr: 6/8mg (MTX/HC), 1-2 yrs: 8/10mg, 2-3 yrs: 10/12mg, \>3 yrs: 12/15 mg. It will be administered (+/- 3 days) on day 7, 14, 21 and 42.
Study: NCT02299167
Drug: Dixon's up-and-down method
Approvals — FDA: no, EMA: no, PMDA: no
Description: using a modified Dixon's up-and-down method (using 0.5 mg as a step size) (16). The first patient was tested at a dose 1.5 mg bupivacaine, if patient responded with failed block then the next patient received an increment of 0.5mg bupivacaine, if patient responded with successful block, then the next patient received a decrement of 0.5mg bupivacaine. The research continued until we obtained seven crossover midpoints.
Study: NCT00777101
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets 2000 mg/m² given orally in two evenly divided daily doses for first 14 days of each 21 day cycle. Given until disease progression or unacceptable toxicity.
Study: NCT04267874
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02395926
Drug: Choline CR 600mg
Normalized name: choline 600 MG
DrugBank: Choline (DB00122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HT-003 600mg, administration 2 times per 1 day 8:00 a.m., 20:00
Study: NCT02395926
Drug: Choline CR 600mg
Normalized name: choline 600 MG
DrugBank: Choline (DB00122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HT-003 600mg\*2tab, administration 1 times per 1 day 8:00 a.m.
Study: NCT01104025
Drug: hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intrathecal Methotrexate and hydrocortisone will be administered to CNS+ patients (CNS+ patients are those patients which have any of the following: elevated CSF (cerebral spinal fluid) protein or white count, seizures, focal or global neurologic deficit, MRI abnormalities consistent with CNS involvement by HLH.) in the following doses: age\< 1 yr: 6/8mg (MTX/HC), 1-2 yrs: 8/10mg, 2-3 yrs: 10/12mg, \>3 yrs: 12/15 mg. It will be administered (+/- 3 days) on day 7, 14, 21 and 42.
Study: NCT01486849
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets BID for 21 days
Study: NCT04160195
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3
Study: NCT00064337
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01452763
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
Study: NCT04330534
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to match BCX9930 capsules for oral administration
Study: NCT00501397
Drug: GSK189075
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00790023
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo HFA Inhaler once daily (one actuation per nostril)
Study: NCT01452763
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-438 placebo-matching tablets, orally, once daily for up to 24 weeks.
Study: NCT03009214
Drug: AMC303
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMC303 is a CD44v6 inhibitor blocking receptor tyrosine kinase (RTK) pathways
Study: NCT00279825
Drug: CD-LD IR
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active comparator containing 25 mg carbidopa and 100 mg levodopa
Study: NCT00279825
Drug: IPX054 200 mg Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match IPX054 200 mg
Study: NCT00279825
Drug: IPX054 250 mg Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match IPX054 250 mg
Study: NCT00279825
Drug: CD-LD IR Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match CD-LD IR
Study: NCT01549002
Drug: Intranasal Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug: Fentanyl 50 micrograms/mL Dosage: 2 micrograms per kilogram (maximum 100 micrograms) Drug delivery: Intranasal via mucosal atomization device (MAD® Nasal, Wolfe Tory Medical Inc., Salt Lake City, UT) Frequency: one-time dose
Study: NCT03631732
Drug: B/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50/200/25 mg FDC tablets administered orally once daily without regard to food
Study: NCT03631732
Drug: NRTIs
Approvals — FDA: no, EMA: no, PMDA: no
Description: The following NRTIs will be administered as prescribed until Week 24 without regard to food:~abacavir (ABC), emtricitabine (FTC), lamivudine (3TC), tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), zidovudine (ZDV or AZT)
Study: NCT03631732
Drug: Third Agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any one of the following third agents will be administered as prescribed. Protease inhibitors and EVG will be administered with the appropriate pharmacologic booster cobicistat or ritonavir. :~* Non-nucleoside reverse transcriptase inhibitors (NNRTIs)~  * delavirdine (DLV)~ * efavirenz (EFV)~ * nevirapine (NVP)~ * rilpivirine (RPV)~ * doravirine (DOR)~* Integrase inhibitors~  * dolutegravir (DTG)~ * elvitegravir (EVG)~ * raltegravir (RAL)~* Protease inhibitors (PIs)~  * atazanavir (ATV)~ * darunavir (DRV)~ * lopinavir (LPV)~ * nelfinavir NFV)~ * saquinavir (SQV)~ * tipranavir (TPV)~* Chemokine co-recptor 5 (CCR5) antagonist --maraviroc (MVC)
Study: NCT02149420
Drug: VAY736
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02149420
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02832973
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone 25 mg
Study: NCT02832973
Drug: Amiloride
Normalized name: Amiloride
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amiloride 5 mg
Study: NCT00004259
Drug: TMZ 200mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/m2 orally on days 1-5 of the first week of radiotherapy. Repeat every 28 days for a total of 12 cycles.
Study: NCT00004259
Drug: BCNU 150mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCNU 150 mg/m2 will be administered as an intravenous infusion on day 5 of radiotherapy, and it will be repeated every eight weeks for a total of six cycles (maximum total BCNU dose 900 mg/m2).
Study: NCT00004259
Drug: BCNU 200mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCNU 200 mg/m2 will be administered as an intravenous infusion on day 1 of radiotherapy and will be repeated every six weeks for a total of 6 cycles (maximum BCNU dose 1200 mg/m2).
Study: NCT00004259
Drug: TMZ 150mg/m2 six 6-week cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/m2 orally on days 1-5 of the first week of radiotherapy. Repeat for a total of six 6-week cycles
Study: NCT00004259
Drug: TMZ 150mg/m2 six 8-week cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/m2 orally on days 1-5 of the first week of radiotherapy. Repeat for a total of six 8-week cycles
Study: NCT03061981
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After pre-dose assessments on Day 1, subjects will receive a single oral dose of IMP after an overnight fast in each Treatment Period.
Study: NCT00833157
Drug: glucosamine sulphate
Normalized name: Glucosamine Sulfate 750 MG Oral Capsule [GLUCOSAMINE SULPHATE]
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects are administered glucosamine-sulphate tablets of 500 mg \* 3 daily, while they are performing a strength-training program with both legs (\*3 weekly) for 12 weeks.
Study: NCT00833157
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects are administered 600 mg \* 2 daily, while they are performing a strength-training program with both legs (\*3 weekly) for 12 weeks
Study: NCT00833157
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects are administered placebo tablets, while they are performing a strength-training program (\*3 weekly) with both legs for 12 weeks
Study: NCT00223028
Drug: sirolimus, mycophenolat mofetil, fluvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01445951
Drug: Technosphere® Insulin with MedTone C Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation Powder and injectable insulin
Study: NCT01796730
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01445951
Drug: Technosphere ®Insulin with Gen2 Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation Powder and injectable insulin
Study: NCT01090882
Drug: Bupivocaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20ml 0.25% at beginning of operation
Study: NCT01090882
Drug: 0.9% normal saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20ml 0.9% NaCl
Study: NCT00272779
Drug: RTV
Normalized name: Accu-Chek SmartView Test Strips
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg Oral Capsules for 96 weeks
Study: NCT01852994
Drug: Testosterone replacement
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Application quarterly of Testosterone Undecylate
Study: NCT00561015
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet to telaprevir will be administered three times a day orally for 2 weeks.
Study: NCT03270735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No snake venom thrombin